AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

The treatment paradigm for unresectable stage III NSCLC: Exploring the growing evidence base

Lecture Time
16:15 - 16:30
Speakers
  • M. Gottfried (Kefar Sava, Israel)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Gottfried (Kefar Sava, Israel)